The facilitatory effects of intermittent theta burst stimulation on corticospinal excitability are enhanced by nicotine.

Plain-language guide to PMID 19640784 (2009): double-blind randomized controlled trial of Therapeutic nicotine (patch, non-peptide) in 10 subjects.

Key Facts

PMID: 19640784
Journal: Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
Year: 2009
Study type: Randomized Controlled Trial
Authors: Swayne OB et al. (4 authors)
DOI: 10.1016/j.clinph.2009.06.013

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

This form of facilitatory plasticity within the stimulated cortex may occur by induction of long term potentiation (LTP).

Who Took Part

The abstract describes 10 subjects taking part.

By PubMed's age tags, the people studied were adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Blinding on both sides kept the subjects and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).

The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.

Each person switched between Therapeutic nicotine (patch, non-peptide) and the comparison at some point, usually with a gap in between.

What Was Measured

Topics PubMed links to this paper include Analysis of Variance, Biophysics, Electromyography, Evoked Potentials, Motor, Nicotine, Nicotinic Agonists and Pyramidal Tracts.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 10 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2009 (Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology), a journal based in Netherlands.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.